New Releases from NCBI BookshelfBrolucizumab (neovascular age-related macular degeneration): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-101 [Internet].​Brolucizumab (neovascular age-related macular degeneration): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-101 [Internet].